PSMA I&T R&D grade
Precursor for radiometal-labelled PSMA I&T
Prostate-specific membrane antigen for imaging & therapy
Molecular Weight:
1498.37
Molecular Formula:
C63H92IN11O23
PSMA I&T (R&D Grade)
General Information
Product name: PSMA I&T
Sequence: D-Lysine, N-[4-carboxy-1-oxo-4-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]butyl]-3-iodo-D-tyrosyl-D-phenylalanyl-N6-[8-[[(5S)-5-carboxy-5-[[[[(1S)-1,3-dicarboxypropyl]amino]carbonyl]amino]pentyl]amino]-1,8-dioxooctyl]
Molecular Weight: 1498.37
Molecular Formula: C63H92IN11O23
Product Description
Labelling precursor for 68Ga, 177Lu and 225Ac [1-4].
For SPECT/CT imaging and radionuclide therapy of prostate cancer (PCa)[5].
For use by qualified personnel only.
For research use only.
Quantity
Product No. 50158: 1mg
Packaging
2 mL Cryovials
Storage and Stability
Storage at -20°C.
Sealed storage, away from moisture.
In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Certificates
Analytical Data Sheet with Chemical Purity by HPLC.
Literature
Literature
[1] Weineisen M. et al. 68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies. J Nucl Med, 2015, 56(8):1169-76.
[2] Fendler WP. et al. 68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0.Eur J Nucl Med Mol Imaging, 2017, 44(6):1014-1024.
[3] Kulkarni HR et al. PSMA-Based Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer: The Bad Berka Experience Since 2013. J Nucl Med. 2016, 57(Suppl 3):97S-104S.
[4] von Eyben FE. et al. Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review. Eur J Nucl Med Mol Imaging, 2018, 45(3):496-508.
[5] Chatalic KL, et al. Towards Personalized Treatment of Prostate Cancer: PSMA I&T, a Promising Prostate-Specific Membrane Antigen-Targeted Theranostic Agent. Theranostics. 2016 Apr 12;6(6):849-6.
